Tumor antigen expression in melanoma varies according to antigen and stage

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 764-771

  Barrow, Catherine ^a   Browning, Judy ^a   MacGregor, Duncan ^a,b   Davis, Ian D ^a   Sturrock, Sue ^b   Jungbluth, Achim A ^a   Cebon, Jonathan ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 4; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROGNOSIS; ULCER;

ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 32944457941     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1544     Document Type: Article

References (42)

1. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997;9:681-3.
2. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-39.
3. Chen YT, Old LJ. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J Sci Am 1999;5:16-7.
4. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
5. + T cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697-702.
6. Gnjatic S, Jager E, Chen W, et al. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A 2002;99:11813-8.
7. + cancers [In Process Citation]. Proc Natl Acad Sci U S A 2000;97:12198-203.
8. Scott AM, Cebon J. Clinical promise of tumour immunology. Lancet 1997;349:51119-22.
9. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003;73:3-29.
10. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-3.
11. Gattoni-Celli S, Cole DJ. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol 1996;23:754-8.
12. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996;19:192-205.
13. de Vries TJ, Fourkour A, Wobbes T et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997;57:3223-9.
14. Cormier JN, Abati A, Fetsch P, et al. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 1998;21:27-31.
15. Kageshita T, Kawakami Y, Hirai S, Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 1997;20:460-5.
16. Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 1996;93:5915-9.
17. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
18. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
19. Coulie PG, Van den Eynde BJ, van der Bruggen P, Van Pel A, Boon T. Antigens recognized by T-lymphocytes on human tumours. Biochem Soc Trans 1997;25:544-8.
20. Sahin U, Tureci O, Chen YT, et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998;78:387-9.
21. Tureci O, Chen YT, Sahin U, et al. Expression of SSX genes in human tumors. Int J Cancer 1998;77:19-23.
22. Hofbauer GF, Schaefer C, Noppen C, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997;151:1549-53.
23. Vaughan HA, Svobodova S, Macgregor D, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 2004;10:8396-404.
24. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;192:856-60.
25. Jungbluth AA, Iversen K, Coplan K, et al. T311-an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract 2000;196:235-42.
26. Chen YT, Stockert E, Chen Y, et al. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A 1994;91:1004-8.
27. Landry C, Brasseur F, Spagnoli GC, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000;186:835-41.
28. Bacchi CE, Bonetti F, Pea M, Martignoni G, Gown AM. HMB-45. A review. Appl Immunohistochem Mol Morphol 1996;4:73-85.
29. Miller RT, Kubier P. Blocking of endogeneous avidin-binding activity in immunohistochemistry. The use of egg whites. Appl Immunohistochem Mol Morphol 1997;5:63-6.
30. Miller RT, Kubier P, Reynolds B, Henry T, Turnbow H. Blocking of endogeneous avidin-binding activity in immunohistochemistry. The use of skim milk as an economical and effective substitute for commercial biotin solutions. Appl Immunohistochem Mol Morphol 1999;7:63-5.
31. de Vries TJ, Smeets M, de Graaf R, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001;193:13-20.
32. Dalerba P, Ricci A, Russo V. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998;77:200-4.
33. Goydos JS, Patel M, Shih W. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 2001;98:76-80.
34. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues [see comments]. Am J Surg Pathol 1998;22:595-602.
35. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 1998;22:57-63.
36. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
37. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
38. Gajjar NA, Cochran AJ, Binder SW. Is MAGE-1 expression in metastatic malignant melanomas really helpful? Am J Surg Pathol 2004;28:883-8.
39. Brasseur F, Rimoldi D, Lie̊nard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-80.
40. Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000;13:459-65.
41. Bolli M, Schultz-Thater E, Zajac P. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 2005;115:960-6.
42. Kurnick JT, Ramirez-Montagut T, Boyle LA, et al. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol 2001;167:1204-11.